LUMICKS Unveils Avidion - A Breakthrough in Cell Therapy
LUMICKS Unveils Avidion - A Breakthrough in Cell Therapy
LUMICKS has launched Avidion, an innovative Cell Avidity platform that transforms how scientists navigate immune drug-tumor interactions. This game-changing technology enables researchers to identify superior cell therapy candidates, grasp underlying mechanisms effectively, and move forward with enhanced confidence.
Understanding the Avidion Technology
Avidion provides clarity in a field where 83% of CAR-T cell therapies fail after preclinical development. Traditional methods often do not adequately predict clinical efficacy, as molecular assays typically measure receptor binding to antigens, while killing assays assess functional outcomes. However, there exists a significant gap that illustrates the physical engagement and interactions between cells. Cell Avidity helps bridge this gap by analyzing the combined strength of cell-to-cell binding, thereby offering deeper insights into the mechanisms of action that contribute to successful drug development.
Significance of Cell Avidity
The importance of Cell Avidity is underscored by its presence in over 50 impactful publications, stemming from more than 70 prominent academic institutions and biotechnology/pharmaceutical companies. This broad validation emphasizes the platform's value in selecting the most effective candidates for further development.
Empowering Researchers
Avidion simplifies the measurement of Cell Avidity, making it accessible to researchers across the globe. With this tool, drug developers can seamlessly integrate Cell Avidity assessments into their research workflows. From screening large panels to conducting detailed characterization studies, Avidion enhances the entire research process, enabling quicker and more informed lead selection that ultimately elevates preclinical success rates. This advancement not only streamlines workflows but also reduces the overall costs associated with creating new cellular therapies.
High-Throughput Capability
Avidion’s high-throughput platform is designed to work with standard 96-well plates, facilitating easy incorporation into established experimental setups. Its fully automated design, supported by machine learning technology, guarantees reproducible and high-quality data, ensuring reliable data collection for users.
Feedback from the Scientific Community
The scientific community has expressed enthusiasm about Avidion's capabilities. Peter Chockley, an assistant professor at The Ohio State University, remarked, "There's something very elegant about the solution. Avidion makes it exceptionally straightforward. You make the layer. You see the cells. There's a building of confidence."
Marcus Barden, a postdoctoral researcher from the Hinrich Abken lab at Regensburg University, stated, "[The] high throughput [and] larger datasets to understand the correlation between binder characteristics and CAR-signaling quantity and quality is definitely the way to go." Such feedback reflects the positive impact Avidion is poised to have on enhancing cell therapy research.
About LUMICKS
LUMICKS stands at the forefront of innovation in life science tools, striving to accelerate drug discovery in cancer research. Their commitment lies in advancing the understanding of essential biological mechanisms at both molecular and cellular levels. By equipping researchers with cutting-edge technologies, LUMICKS facilitates the unearthing of vital insights into the biological complexities associated with health and disease, thereby driving the development of next-generation therapies. Their efforts significantly contribute to the acceleration of immunotherapy breakthroughs.
Frequently Asked Questions
What is Avidion?
Avidion is a next-generation Cell Avidity platform by LUMICKS that enhances the measurement and understanding of immune drug-tumor interactions.
How does Avidion improve cell therapy development?
Avidion improves the selection process for potential cell therapy candidates and helps predict their efficacy by providing insights through measurements of cell binding strength.
What benefits does Avidion offer researchers?
It offers a high-throughput platform that integrates well with existing workflows and delivers reliable, high-quality data for informed decision-making.
What has been the feedback from users of Avidion?
Users have praised its elegance and ease of use, highlighting its ability to build confidence in observations of cell interactions.
What is the mission of LUMICKS?
LUMICKS aims to accelerate drug discovery and deepen understanding of fundamental biological mechanisms, ultimately contributing to breakthroughs in immunotherapy.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
